Eli Lilly agreed to a $2.75B AI-focused drug deal with Insilico, signaling sizable corporate commitment to AI-driven drug discovery. The transaction has heightened investor interest in healthcare ETFs as a diversified way to access the fast-growing AI-enabled pharma theme and could lift sector/ETF flows and select biotech/pharma equities.
Eli Lilly agreed to a $2.75B AI-focused drug deal with Insilico, signaling sizable corporate commitment to AI-driven drug discovery. The transaction has heightened investor interest in healthcare ETFs as a diversified way to access the fast-growing AI-enabled pharma theme and could lift sector/ETF flows and select biotech/pharma equities.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.60
